CDISC Public Webinar – Standards Updates and Additions

Oct 7 2015
Agenda

• Breast Cancer TA Public Review
  ▪ John Owen, CDISC
  ▪ Erin Muhlbradt, NCI-NIH
  ▪ Susan Kenny, Maximum Likelihood
  ▪ Elizabeth Langevin, Takeda
  ▪ Barrie Nelson, Onyx
  ▪ Jeanne Schilder, Lilly

• CDISC Online Education & Event Updates
  ▪ John Ezzell, CDISC
Question & Answer

• ‘Panelist’: Question
  OR
• ‘Presentation’: Question

Examples:

Amy: What are new updates in the Virology TAUG?  
OR
CDISC: When can we start registering for the US Interchange?
Breast Cancer
Therapeutic Area User Guide

Education Webinar Presentation
Wednesday 7th October 2015
10:00-11:30 CST
• Introduction to Breast Cancer

• Breast Cancer Therapeutic Area User Guide (TAUG)

• Domains

• Variables

• Controlled Terminology

• Analysis Data

• Public Review Information
• October 2015 is Breast Cancer Awareness Month

• Breast cancer is a solid tumor cancer arising in the epithelial cells of the breast (mainly in the milk ducts or glands)

• Breast cancer is the most frequently diagnosed cancer in women worldwide (including developed and developing countries)

• Breast Cancer is the leading cause of cancer death in women
  • 23% of total cancer cases
  • 14% of cancer deaths

• Breast cancer also occurs in men, but it is rare

Introduction to Breast Cancer

- Risk factors for breast cancer include
  - Sex
  - Age
  - Family history
  - Early menarche
  - Late menopause
  - Postmenopausal obesity
  - Use of combined estrogen and progestin menopausal hormones
  - Cigarette smoking
  - Alcohol consumption

- The etiology of breast cancer is influenced by diet as well as hormonal and reproductive factors.

- Treatment options may include combinations of surgery, radiation therapy, chemotherapy, and hormone therapy.

- Breast Cancer background provided in Appendix E – Clinical Background

- Further reading suggestions can be found in Appendix F2

• Final SRC review comments currently being addressed
• Anticipated Public Review Release date 19th October 2015
• Anticipated review comments closing date 18th November 2015
An overview of the Breast Cancer TAUG is represented in the following document diagram.
• References to SDTM Examples for Oncology Use Cases
Breast Cancer - TAUG

- Standard Section 1
  - PURPOSE
  - ORGANIZATION OF THIS DOCUMENT
  - CONCEPT MAP GENERAL INFORMATION
  - CONTROLLED TERMINOLOGY GENERAL INFORMATION
  - RELATIONSHIPS TO OTHER STANDARDS
  - KNOWN ISSUES
• Section 2 – **New**: Overview of Breast Cancer
Breast Cancer treatment can be described in terms of the intent and setting and endpoints associated with these settings.
Breast Cancer - TAUG

- Therapeutic Area Users Guides are organised by kinds of data collected
- Section 2: Overview of Breast Cancer includes a matrix that links the different settings to the various use cases

<table>
<thead>
<tr>
<th>Use Case</th>
<th>Example</th>
<th>Neoadjuvant</th>
<th>Adjuvant</th>
<th>Advanced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen receptor status</td>
<td>Section 3.3.1 Example 1</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Gross pathology</td>
<td>Section 3.3.1 Example 2</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Prior anti-neoplastic therapy</td>
<td>Section 3.4.1 Example 1</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Prior radiotherapy</td>
<td>Section 3.4.1 Example 2</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>On-study surgeries</td>
<td>Section 4.1.1 Example 1</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>On-study radiotherapy</td>
<td>Section 4.1.1 Example 1</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Tumor identification: target lesions</td>
<td>Example CRF 2</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Tumor identification: non-target lesions</td>
<td>Example CRF 3</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Tumor identification: new lesions</td>
<td>Example CRF 4</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Disease Response</td>
<td>Example CRF 5</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Tumor imaging and assessment</td>
<td>Section 4.2.1 Example 1</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Section 4.2.1 Example 1</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Section 4.2.1 Example 2</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Disease Response</td>
<td>Section 4.3.1 Example 2</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Section 2: Overview of Breast Cancer also includes links to the various endpoints described in the analysis section.

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Setting</th>
<th>TAUG Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathologic Complete Response (pCR)</td>
<td>Neoadjuvant</td>
<td>Not included*</td>
</tr>
<tr>
<td>Event Free Survival (EFS)</td>
<td>Neoadjuvant</td>
<td>Analysis Section 5.1.1.3</td>
</tr>
<tr>
<td>Disease Free Survival (DFS)</td>
<td>Adjuvant</td>
<td>Analysis Section 5.1.1.4</td>
</tr>
<tr>
<td>Overall Survival (OS)</td>
<td>Neoadjuvant, Adjuvant, Advanced</td>
<td>Analysis Section 5.1.1.2</td>
</tr>
<tr>
<td>Progression Free Survival (PFS)</td>
<td>Advanced</td>
<td>Analysis Section 5.1.1.1</td>
</tr>
</tbody>
</table>

*NOTE: Pathologic Complete Survival (pCR) is not described in the analysis section because the final analysis of a binary endpoint is simple, and the derivation of the endpoint depends on the definition used, which will vary by study*
• Section 3 – Subject and Disease Characteristics
Breast Cancer - TAUG

- Section 4 – Disease Management and Assessments
Breast Cancer - TAUG

- Section 5 – Analysis Data (detail covered later)
Breast Cancer - TAUG

- Appendices
  - PROJECT PROPOSAL
  - CFAST BRCA TEAM
  - GLOSSARY AND ABBREVIATIONS
  - NON-STANDARD VARIABLES
  - CLINICAL BACKGROUND
  - REFERENCES
  - REPRESENTATIONS AND WARRANTIES, LIMITATIONS OF LIABILITY, AND DISCLAIMERS
Domains

- No new domains were submitted for this version of the TAUG
- The following Domains are referenced in the TAUG

<table>
<thead>
<tr>
<th>Datasets</th>
<th>Description</th>
<th>Section in TA User Guide</th>
<th>Link*</th>
<th>Section Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>MI</td>
<td>Microscopic Findings</td>
<td>3.3.1 Ex 1</td>
<td></td>
<td>Pathology - Estrogen Receptor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.3.1 Ex 2</td>
<td>1</td>
<td>Pathology – Surgical Margin Status</td>
</tr>
<tr>
<td>MO</td>
<td>Morphology</td>
<td>3.3.1 Ex 2</td>
<td>1</td>
<td>Pathology – Lumpectomy Measurements</td>
</tr>
<tr>
<td>CM</td>
<td>Concomitant Medications</td>
<td>3.4.1 Ex 1</td>
<td></td>
<td>Prior Treatments - Prior Antineoplastic Therapies</td>
</tr>
<tr>
<td>PR</td>
<td>Procedures</td>
<td>3.4.1 Ex 2</td>
<td></td>
<td>Prior Treatments - Prior Antineoplastic Radiotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.1.1 Ex 1</td>
<td></td>
<td>Treatments – Lumpectomy/Lymph Node Dissection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.1.1 Ex 2</td>
<td></td>
<td>Treatments – Radiation with Different Schedules</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.2.1 Ex 1</td>
<td>2</td>
<td>Tumor ID/Assessments/Response – Screening CT Scan/Scintigraphy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.2.1 Ex 2</td>
<td>3</td>
<td>Tumor ID/Assessments/Response – Screening/Post-Screening CT Scan/Scintigraphy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.3.1 Ex 1</td>
<td>4</td>
<td>Disease Recurrence - Screening/Post-Screening CT Scan/MRI</td>
</tr>
<tr>
<td>TU</td>
<td>Tumor Identification</td>
<td>4.2.1 Ex 1</td>
<td>2</td>
<td>Tumor ID/Assessments/Response – Screening Tumor Identification</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.2.1 Ex 2</td>
<td>3</td>
<td>Tumor ID/Assessments/Response – Screening Tumor Identification</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.3.1 Ex 1</td>
<td>4</td>
<td>Tumor ID/Assessments/Response – Post-Screening Tumor Identification</td>
</tr>
<tr>
<td>RS</td>
<td>Disease Response</td>
<td>4.2.1 Ex 2</td>
<td>3</td>
<td>Tumor ID/Assessments/Response – Post-Screening Response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.3.1 Ex 1</td>
<td>4</td>
<td>Disease Recurrence – Post-Screening Response</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.3.1 Ex 2</td>
<td></td>
<td>Disease Recurrence – Pathologic Complete Response (pCR)</td>
</tr>
</tbody>
</table>

* Link identifies those domains that are used within the same example
• No new standard variables were submitted for this version of the TAUG

• Non-Standard Variables
  • This document has adopted the practices outlined in the proposed SDTMIG Section 8.4.4, Alternative Representation of Non-Standard Variables (also called the NSV Proposal; circulated for public review as part of SDTMIG v3.3 Batch 2).
  • SDTM examples containing sample data requiring the use of a variable outside the standard set of variables included in SDTM v1.4 are represented not with supplemental qualifier records but with non-standard variables (NSVs) appended to the end of the parent domain
  • Sample value-level metadata for NSVs are given in tabulated form following each dataset in which they are used, and also in Appendix D. NSVs have been rendered visually distinct with white text on black in the header row, and separated from the standard variables by a small space.
- Example NSV format in Prior Radiation Therapy Use Case
**Variables**

- The following NSV’s were proposed for version 1 of the Breast Cancer TAUG

<table>
<thead>
<tr>
<th>Parent Domain</th>
<th>Variable Name</th>
<th>Variable Label</th>
<th>Type</th>
<th>Controlled Terms, Codelist, or Format</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>CM</td>
<td>RSDISC</td>
<td>Reason for Discontinuation</td>
<td>text</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM, PR</td>
<td>STT</td>
<td>Setting</td>
<td>text</td>
<td>Treatment Setting (TRTMSTT)*</td>
<td></td>
</tr>
<tr>
<td>CM, PR</td>
<td>TRTINT</td>
<td>Treatment Intent</td>
<td>text</td>
<td>Treatment Intent (TRTINTNT)*</td>
<td></td>
</tr>
<tr>
<td>MI</td>
<td>PTSCL</td>
<td>Point Scale</td>
<td>text</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>CMLDOS</td>
<td>Cumulative Dose</td>
<td>float</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>OUTTRT</td>
<td>Treatment Outcome</td>
<td>**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>PRLOCn</td>
<td>Procedure Location n</td>
<td>text</td>
<td>Anatomical Location (C74456)</td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>RTTLFR</td>
<td>Total Fractions Count</td>
<td>integer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>TRTDTL</td>
<td>Treatment Detail</td>
<td>text</td>
<td>**</td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>TRTLOC</td>
<td>Treatment-Relative Location</td>
<td>text</td>
<td>**</td>
<td></td>
</tr>
<tr>
<td>TU</td>
<td>LOCTXT</td>
<td>Location Text</td>
<td>text</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Description/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSDISC</td>
<td>The reason for ceasing (prior/concomitant) treatment.</td>
</tr>
<tr>
<td>STT</td>
<td>The setting as characterized by the purpose of the study treatment in relation to the primary treatment.</td>
</tr>
<tr>
<td>TRTINT</td>
<td>The therapeutic intent of the treatment.</td>
</tr>
<tr>
<td>PTSCL</td>
<td>When the score is determined by a multi-point scale, how many points are on the scale.</td>
</tr>
<tr>
<td>CMLDOS</td>
<td>For treatments with a cumulative effect, the total dose administered over the time period defined by --STDTC and --ENDTC. Used instead of --DOSE.</td>
</tr>
<tr>
<td>OUTTRT</td>
<td>The best outcome of the (prior) treatment.</td>
</tr>
<tr>
<td>PRLOCn</td>
<td>Used when PRLOC = MULTIPLE; n stands for an integer between 1 and the maximum number of locations needed.</td>
</tr>
<tr>
<td>RTTLFR</td>
<td>How many fractions of the intended total dose were administered.</td>
</tr>
<tr>
<td>TRTDTL</td>
<td>Further description of --TRT. In this document, this variable is used to hold the modality of the treatment.</td>
</tr>
<tr>
<td>TRTLOC</td>
<td>The location of the treatment’s target, relative to the primary site of disease.</td>
</tr>
<tr>
<td>LOCTXT</td>
<td>Specifies the exact location of the identified tumor or lesion for identification purposes; used when --LOC, --LAT, and --DIR are not enough to distinguish it from another tumor/lesion in the same anatomical location.</td>
</tr>
</tbody>
</table>
Summary of Controlled Terminology Developed during the Breast Cancer Project

<table>
<thead>
<tr>
<th>Batch</th>
<th>Details</th>
<th>Status</th>
</tr>
</thead>
</table>
| 1     | • New test terminology for MI, TU, RS  
      | • New response terminology for TU  
      | • New values for LOC, METHOD                                      | Published with P23 publication on 2015-09-25     |
| 2     | • New test terminology for TR, RS, SS  
      | • New response terminology for SS  
      | • New response codelists for suppquals                      | Out for public review.  
      |                                           | • Treatment Intent  
      |                                           | • Treatment Setting  
      |                                           | • New response terminology for TU  
      |                                           | • New values for METHOD, PROCEDUR               | Will be published with P24 publication on 2015-12-18 |
| 3     | • New codelist for MITSTDTL variable  
      | • New response terminology for TR                                      | Will go out for public review with P25 in December 2015 |
Analysis Data – Section Overview

Key Analysis Endpoints
- Survival Analysis
  - Progression Free Survival - PFS
  - Overall Survival - OS
  - Event Free Survival - EFS
  - Disease Free Survival - DFS
- Response Rate
- Best Overall Response (BOR)
- Duration of Response (DOR)

Table Shells

Analysis Datasets

Subject Level

Event Reporting

Efficacy Reporting

Categorical Analysis of Tumor Response

Analysis of Time to Progression

ADSL variable metadata

ADEVENT variable metadata

ADTTE variable metadata

ADRESP variable metadata

ADaM adsi.xpt example

ADaM adevent.xpt example

ADaM adtte.xpt example

ADaM adresp.xpt example
Approach for the Creation of Analysis Datasets

SDTM → ADEVENT → Interim BDS dataset for curation of source data

- TTE
- Response Rates
• Important subject level variables that would typically appear in ADSL are shown

• An approach of using a BDS based intermediate dataset is shown. This intermediate dataset assembles all information that is used for the derivation of analysis variables related to time to event and response analyses.

• Other BDS datasets are derived from the intermediate dataset for analysis of time to event and best response rates

• As with other TAUGs, these are examples of ADaM implementation and should not be interpreted as standards in and of themselves. Statistical methodology is not discussed
Public Review

- Review Package Contents (will be made available on the CDSIC Portal)
  - TAUG File in PDF format
  - Readme file
  - CDASH Metadata Excel File
  - Document Reference Map

- Link to Oncology Use Cases Excel Sheet on CDISC Website

- CDISC Public Comment Tracker
  - Location => [http://portal.cdisc.org/CT/default.aspx](http://portal.cdisc.org/CT/default.aspx)
  - Instructions => [http://portal.cdisc.org/CT/Pages/CCTT-Help.aspx](http://portal.cdisc.org/CT/Pages/CCTT-Help.aspx)

- Recommend to check the Known Issues Section 1.6 prior to review of the TAUG
• Anticipated Review Period (pending resolution of SRC comments)
Breast Cancer
Therapeutic Area User Guide

Education Webinar Presentation
Wednesday 7th October 2015
10:00-11:30 CST
Thank you!
CDISC Education Events
Announcements

Learn CDISC from CDISC!
Standard currently out for review

- Controlled Terminology P24
  - Visit [http://cdisc.org/terminology](http://cdisc.org/terminology) for more information
  - Comments due 9 October 2015

Click [here](http://cdisc.org/terminology) to submit your comments.
# Upcoming North America Public Courses and Events

<table>
<thead>
<tr>
<th>Location</th>
<th>Dates</th>
<th>Courses Offered</th>
<th>Host</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambridge, MA</td>
<td>12-16 Oct 2015</td>
<td>SDTM-PK, SDTM, ADaM, Define-XML</td>
<td>Alexion</td>
</tr>
<tr>
<td>Chicago, IL (International Interchange)</td>
<td>9, 12-13 Nov</td>
<td>See website</td>
<td>CDISC</td>
</tr>
<tr>
<td>Morrisville, NC</td>
<td>9-12 Feb 2016</td>
<td>SDTM, CDASH, ADaM</td>
<td>SynteractHCR</td>
</tr>
<tr>
<td>Audubon, PA</td>
<td>2-11 Mar 2016</td>
<td>Courses corresponding to standards listed in Data Standards Catalog. See web.</td>
<td>BioClinica</td>
</tr>
</tbody>
</table>

Visit [cdisc.org/public-courses](http://cdisc.org/public-courses) for information on other CDISC Public Training events.

Check CDISC website for up-to-date information on Public Courses.
## Upcoming Europe Public Courses and Events

<table>
<thead>
<tr>
<th>Location</th>
<th>Dates</th>
<th>Courses Offered</th>
<th>Host</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copenhagen, Denmark</td>
<td>28 Oct - 3 Nov 2015</td>
<td>SDTM, ADaM, SEND</td>
<td>SCUBED</td>
</tr>
<tr>
<td>Berkshire, UK</td>
<td>26-29 Jan 2016</td>
<td>SDTM, ADaM, Define-XML</td>
<td>QUINTILES</td>
</tr>
<tr>
<td>Paris, France</td>
<td>8-11 Mar 2016</td>
<td></td>
<td>SANOFI</td>
</tr>
<tr>
<td>Europe Interchange in Vienna, Austria</td>
<td>25-29 Apr 2016</td>
<td></td>
<td>CDISC</td>
</tr>
</tbody>
</table>

*Registration deadline indicates online deadline. Onsite registration is available before each event begins. Additional 2015 public training events can be found [@http://cdisc.org/public-courses](http://cdisc.org/public-courses).*

Full 2016 Public Training Schedule is online

Check CDISC website for up-to-date information on Public Courses
## Upcoming Asia Public Courses and Events

<table>
<thead>
<tr>
<th>Location</th>
<th>Dates</th>
<th>Courses Offered</th>
<th>Register by:</th>
<th>Early Registration Discounts</th>
<th>Host</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beijing, China</td>
<td>20-23 Oct 2015</td>
<td>SDTM, CDASH, ADaM, ODM, Define-XML</td>
<td>20 Sep 2015</td>
<td>Expired</td>
<td>PPD</td>
</tr>
<tr>
<td>Shanghai, China</td>
<td>26-29 Oct 2015</td>
<td>SDTM, CDASH, ADaM, ODM, Define-XML</td>
<td>20 Sep 2015</td>
<td>Expired</td>
<td>GSK</td>
</tr>
<tr>
<td>Tokyo, Japan</td>
<td>14-18 Dec 2015</td>
<td>SDTM, CDASH, ADaM, ODM, Define-XML</td>
<td>13 Nov 2015</td>
<td>13 Nov 2015</td>
<td>EXCARE CAC EXICARE Corporation</td>
</tr>
</tbody>
</table>

Visit [http://cdisc.org/public-courses](http://cdisc.org/public-courses) for information on other CDISC Public Training events in Asia.

Check CDISC website for up-to-date information on Public Courses
In-House Classroom Training

www.cdisc.org/private-courses

Benefits:

• Learn with your group using specific use cases and implementation questions
• On-location authorized instructor
• Cost-effective group training
Licensed Training - Exclusively for our Members

http://www.cdisc.org/licensed-training-subpage

Benefits:

- Standard qualification and training process
- All materials developed by standards teams
- Your instructor delivers training
- Training when your staff needs it
- Official CDISC Education certificates

You get the best training, just when you need it, and save time and money!
CDISC Online Training

Cdisc.trainingcampus.net

- Online training created with support from CDISC standards development teams
- New CDISC trainings developed in tandem with standards development
- Online courses benefits:
  - flexibility
  - more content
  - greater depth
  - updated frequently
Next Members Only Webinar

• **Agenda:**
  - EPOCH Variable

• **Date:** 22 Oct 2015, 11:00-12:30 PM EST

• **Speakers:**
  - Diane Wold, CDISC

• Register [here](#).

*Webinar details also at [www.cdisc.org/webinars](http://www.cdisc.org/webinars)*

© CDISC 2015
Any more questions?

Thank you for attending this webinar.

CDISC’s vision is to:
Inform Patient Care & Safety Through Higher Quality Medical Research
CDISC Members Drive Global Standards

Thank you for your support!

Learn CDISC from CDISC!